Wendy Darlington
Advanced in Hemoglobinopathy

Dr. Wendy Darlington

Hematology | Oncology
Endeavor Health
The University Of Chicago Medical Center
5721 S Maryland Ave, 2nd Flr, 
Chicago, IL 

Advanced in Hemoglobinopathy
Endeavor Health
The University Of Chicago Medical Center
5721 S Maryland Ave, 2nd Flr, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Wendy Darlington is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Darlington is rated as an Advanced provider by MediFind in the treatment of Hemoglobinopathy. Her top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia.

Her clinical research consists of co-authoring 8 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles in the study of Hemoglobinopathy.

Graduate Institution
University Of Texas - Galveston, 2009
Residency
University of Texas Southwestern Medical Center (Dallas), Pediatrics, 2012
Specialties
Hematology
Oncology
Licenses
Pediatric Hematology-Oncology in IL
Board Certifications
American Board Of Pediatrics
Fellowships
University of Chicago - Pritzker School of Medicine, Pediatrics, 2015
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 6 Less Insurance Carriers -

Locations

The University of Chicago Medical Center
5721 S Maryland Ave, 2nd Flr, Chicago, IL 60637
Call: 773-702-6808

Additional Areas of Focus

Dr. Darlington has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


6 Clinical Trials

A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Selumetinib, Vinblastine
Study Phase: Phase 3
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Enrollment Status: Active_not_recruiting
Publish Date: December 22, 2025
Intervention Type: Drug, Procedure, Radiation, Other
Study Drugs: Cisplatin, Cyclophosphamide, Lomustine, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
Enrollment Status: Active_not_recruiting
Publish Date: October 27, 2025
Intervention Type: Drug, Radiation, Biological, Other
Study Drugs: Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Vincristine
Study Phase: Phase 3
View 5 Less Clinical Trials

8 Total Publications

Differences in Inpatient Palliative Care Consultation During the Terminal Admission for Pediatric Neuro-Oncology Patients.
Differences in Inpatient Palliative Care Consultation During the Terminal Admission for Pediatric Neuro-Oncology Patients.
Journal: The American journal of hospice & palliative care
Published: January 29, 2025
View All 8 Publications
Similar Doctors
Elite in Hemoglobinopathy
Dr. Santosh L. Saraf
Hematology Oncology | Hematology | Oncology
Elite in Hemoglobinopathy
Dr. Santosh L. Saraf
Hematology Oncology | Hematology | Oncology

The Board Of Trustees Of The University Of Illinois

1740 W Taylor St, 
Chicago, IL 
 (6.5 miles away)
Languages Spoken:
English
See accepted insurances

Santosh Saraf is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Saraf is rated as an Elite provider by MediFind in the treatment of Hemoglobinopathy. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

Elite in Hemoglobinopathy
Dr. Robert E. Molokie
Hematology Oncology | Hematology | Oncology
Elite in Hemoglobinopathy
Dr. Robert E. Molokie
Hematology Oncology | Hematology | Oncology

The Board Of Trustees Of The University Of Illinois

1855 W Taylor St, Mc648, 
Chicago, IL 
 (6.6 miles away)
312-996-6590
Languages Spoken:
English
See accepted insurances

Robert Molokie is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Molokie is rated as an Elite provider by MediFind in the treatment of Hemoglobinopathy. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Hemolytic Anemia, and Bone Marrow Transplant.

Elite in Hemoglobinopathy
Dr. Shivi Jain
Hematology
Elite in Hemoglobinopathy
Dr. Shivi Jain
Hematology

Rush University Medical Group

610 S Maple Ave, Suite 2000, 
Oak Park, IL 
 (12.0 miles away)
312-942-4444
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shivi Jain is a Hematologist in Oak Park, Illinois. Dr. Jain is rated as a Distinguished provider by MediFind in the treatment of Hemoglobinopathy. Her top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Hemoglobin E Disease, Hemoglobin C Disease, and Bone Marrow Transplant.

VIEW MORE HEMOGLOBINOPATHY DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Darlington's expertise for a condition
ConditionClose
      • Advanced
      • Anemia
        Dr. Darlington is
        Advanced
        . Learn about Anemia.
        See more Anemia experts
      • Congenital Hemolytic Anemia
        Dr. Darlington is
        Advanced
        . Learn about Congenital Hemolytic Anemia.
        See more Congenital Hemolytic Anemia experts
      • Hemoglobinopathy
        Dr. Darlington is
        Advanced
        . Learn about Hemoglobinopathy.
        See more Hemoglobinopathy experts
      • Hemolytic Anemia
        Dr. Darlington is
        Advanced
        . Learn about Hemolytic Anemia.
        See more Hemolytic Anemia experts
      • Sickle Cell Disease
        Dr. Darlington is
        Advanced
        . Learn about Sickle Cell Disease.
        See more Sickle Cell Disease experts
      • Experienced
      • Glioma
        Dr. Darlington is
        Experienced
        . Learn about Glioma.
        See more Glioma experts
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile
      For Patients
      • Our Story
      • How MediFind Works
      • Conditions A-Z
      • Doctor Directory
      • Symptoms Directory
      • Procedures Directory
      • Treatment Directory
      • Drug Directory
      • Infusion Center Finder
      • FAQ
      • Contact Us
      For Providers and Practices
      • Claim Your Profile
      • Newsroom
      Business Solutions
      • Provider
      • Network Solutions
      Additional Resources
      • Consumer Health Data Privacy Policy
      • Privacy Policy
      • Terms of Use
      • Advertising Policy
      • Content Policy
      Subscribe to our newsletter

      Sign up to stay informed about MediFind and get wellness sent your way.

      Close

        By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

        Bullet PinMediFind
        Follow us on
        This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
        © 2026 All Rights Reserved

        Request an Appointment

        If you are experiencing a medical emergency, call 9-1-1.

        MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

        Patient Details

        This information is for the patient who will be seen at the appointment.

          Close

          Returning patient? Use your address on file with the provider.

          Insurance Details

          Please provide information of the primary insurance holder as the practice may require this information to schedule.

          Insurance Provider *
          Insurance ProviderClose

          Appointments Details

          Let’s get more information about your appointment.

                  0 / 1000
                  0 / 1000
                  By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.